Law360, New York (November 02, 2009) -- Apotex Inc.'s legal dispute with Sanofi-Aventis over blood-thinning drug Plavix has hit a dead end, with the U.S. Supreme Court refusing to hear the generic-drug maker's arguments over whether substances produced by so-called obvious-to-try experiments should be patentable.
The Supreme Court denied Apotex's petition for a writ of certiorari Monday, the last in a string of decisions against Apotex in the dispute....
